Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of human anti-vegfr2 antibody and its application

A technology of growth factor receptors and heavy chains, applied in the fields of application, anti-tumor drugs, anti-growth factor immunoglobulins, etc., can solve the problems such as the complex molecular regulation mechanism of tumor angiogenesis, and achieve the effect of great application value

Active Publication Date: 2020-03-24
四川泸州步长生物制药有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Tumor blood vessels provide sufficient oxygen and nutrients for tumor occurrence and development. Targeting tumor angiogenesis can achieve the therapeutic effect of starving tumors. However, the molecular regulation mechanism of tumor angiogenesis is very complicated, requiring many growth factors, receptors and signaling pathways Mediated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of human anti-vegfr2 antibody and its application
  • A kind of human anti-vegfr2 antibody and its application
  • A kind of human anti-vegfr2 antibody and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1, Discovery of VEGFR2 specific antibody

[0037] 1. Establishment of human monoclonal antibody library

[0038] Peripheral blood was obtained from 30 volunteers who gave informed consent, and lymphocytes were isolated and total RNA was extracted. Total RNA was reverse transcribed to obtain cDNA. Using cDNA as a template, the variable regions (VH and VL) of the antibody heavy and light chains were amplified by PCR using degenerate primers. The PCR products were subjected to 1% agarose gel electrophoresis, and VH DNA and VL DNA were recovered, and were ligated into a single-chain antibody (scFv) gene by overlapping PCR. The single-chain antibody genes from different volunteers were mixed in equal amounts, grouped and cut with endonucleases, and then subjected to 1% agarose gel electrophoresis, and the DNA fragments were recovered and connected to phagemid vectors that had been cut with the same endonucleases Plasmid, the ligated phagemid carrier plasmid was tr...

Embodiment 2

[0044] Embodiment 2, the acquisition of recombinant cells

[0045] 1. Construction of recombinant plasmids

[0046] 1. Synthesize a DNA molecule (double-stranded DNA molecule shown in sequence 2 of the sequence listing) encoding the heavy chain of the VEGFR2 specific antibody and use it as a template, and use a primer pair consisting of H-F and H-R to carry out PCR amplification to obtain PCR amplification product.

[0047] H-F: GGCAAA GAATTC GCCGCCACC ATGGAACTGGGGCTCCGCTG;

[0048] H-R: GAGCTC GAATTC CTATTTACCCGGAGACAGGGAG.

[0049] 2. Digest the PCR amplified product obtained in step 1 with restriction endonuclease EcoR I, and recover the digested product.

[0050] 3. Digest the pCMV-Myc plasmid with restriction endonuclease EcoR I, and reclaim the vector backbone.

[0051] 4. Ligate the digested product of step 2 with the vector backbone of step 3 to obtain recombinant plasmid pCMV-H.

[0052] 5. Synthesize a DNA molecule encoding the light chain of the VEGFR2 specif...

Embodiment 3

[0063] Example 3, Large-scale preparation and purification of VEGFR2 specific antibody

[0064] CD07V4 medium: the product of Shanghai Opmai Company. PFF06 feed medium: the product of Shanghai Optimai Company. The full name of MTX is methotrexate.

[0065] 1. Take the recombinant cells obtained in Example 2, inoculate them into CD07V4 medium containing 400nM MTX, and culture them with shaking at 37°C until the cell density is (2-4)×10 6 cells / ml.

[0066] 2. Using a 20-liter working volume reactor from Applikon, the Netherlands, to cultivate cells for protein production. Inoculate 2500ml of the culture system that completed step 1 into 10 liters of CD07V4 medium, and culture at 36.5±0.5°C for 15 days (during the cultivation, control the pH to 7.0±0.05; -0.05vvm, dissolved oxygen set point 40%; cell density reaches 5×10 6 cells / ml to start feeding, every 48 hours to add a volume of 5% PFF06 feeding medium of the culture system).

[0067] 3. After step 2 is completed, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a humanized anti-VEGFR2 antibody and application of the humanized anti-VEGFR2 antibody. The provided humanized anti-VEGFR2 antibody is an IgG, a heavy chain of the humanized anti-VEGFR2 antibody comprises a heavy chain variable region and a heavy chain constant region, a light chain of the humanized anti-VEGFR2 antibody comprises a light chain variable region and a light chain constant region; CDR1, CDR2 and CDR3 in the heavy chain variable region are sequentially 45-54th amino acid residues, 69-85th amino acid residues and 118-124th amino acid residues from the N tail end in a sequence 1 of a sequence table; CDR1, CDR2 and CDR3 in the light chain variable region are sequentially 44-54th amino acid residues, 70-76th amino acid residues and 109-117th amino acid residues from the N tail end in a sequence 3 of the sequence table. The humanized anti-VEGFR2 antibody has an important application value on the treatment of tumors and diseases caused by proliferation and migration of human umbilical vein endothelial cells.

Description

technical field [0001] The invention relates to a human anti-VEGFR2 antibody and its application. Background technique [0002] Tumor blood vessels provide sufficient oxygen and nutrients for tumor occurrence and development. Targeting tumor angiogenesis can achieve the therapeutic effect of starving tumors. However, the molecular regulation mechanism of tumor angiogenesis is very complicated, requiring many growth factors, receptors and signaling pathways mediation. [0003] Vascular endothelial growth factor (VEGF) is an essential cytokine for angiogenesis, and VEGFR2 is one of the three receptors of VEGF, which is mainly responsible for the signal pathway transduction of angiogenesis. [0004] Bevacizumab, an inhibitor against VEGF, is a recombinant humanized monoclonal antibody against VEGF developed by Genentech, which is composed of 93% human and 7% mouse. On February 26, 2004, it was approved by the FDA and launched in the United States. It is the first drug for inh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/22C12N15/13A61P9/14A61P35/00
Inventor 杨春原野洪海燕李小雯叶宇
Owner 四川泸州步长生物制药有限公司